X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA DIVIS LABORATORIES NATCO PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 29.1 30.3 95.7% View Chart
P/BV x 22.0 5.3 418.7% View Chart
Dividend Yield % 0.5 0.9 55.2%  

Financials

 NATCO PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
DIVIS LABORATORIES
Mar-17
NATCO PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs8771,222 71.8%   
Low Rs424784 54.0%   
Sales per share (Unadj.) Rs223.4153.1 145.9%  
Earnings per share (Unadj.) Rs31.139.9 77.8%  
Cash flow per share (Unadj.) Rs40.344.6 90.3%  
Dividends per share (Unadj.) Rs5.0010.00 50.0%  
Dividend yield (eoy) %0.81.0 77.1%  
Book value per share (Unadj.) Rs219.5201.8 108.8%  
Shares outstanding (eoy) m33.07265.47 12.5%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.96.6 44.4%   
Avg P/E ratio x20.925.1 83.4%  
P/CF ratio (eoy) x16.122.5 71.8%  
Price / Book Value ratio x3.05.0 59.6%  
Dividend payout %16.125.0 64.3%   
Avg Mkt Cap Rs m21,504266,266 8.1%   
No. of employees `000NA9.7 0.0%   
Total wages/salary Rs m1,1284,687 24.1%   
Avg. sales/employee Rs ThNM4,175.0-  
Avg. wages/employee Rs ThNM481.5-  
Avg. net profit/employee Rs ThNM1,089.3-  
INCOME DATA
Net Sales Rs m7,38940,643 18.2%  
Other income Rs m167749 22.3%   
Total revenues Rs m7,55641,392 18.3%   
Gross profit Rs m1,79314,460 12.4%  
Depreciation Rs m3041,233 24.7%   
Interest Rs m36623 1,620.4%   
Profit before tax Rs m1,29013,953 9.2%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3093,349 9.2%   
Profit after tax Rs m1,02710,604 9.7%  
Gross profit margin %24.335.6 68.2%  
Effective tax rate %23.924.0 99.7%   
Net profit margin %13.926.1 53.3%  
BALANCE SHEET DATA
Current assets Rs m3,68140,105 9.2%   
Current liabilities Rs m3,1236,595 47.4%   
Net working cap to sales %7.682.5 9.2%  
Current ratio x1.26.1 19.4%  
Inventory Days Days89119 75.5%  
Debtors Days Days5981 72.7%  
Net fixed assets Rs m7,68519,995 38.4%   
Share capital Rs m331531 62.3%   
"Free" reserves Rs m6,67053,043 12.6%   
Net worth Rs m7,25953,574 13.5%   
Long term debt Rs m9550-   
Total assets Rs m11,95761,585 19.4%  
Interest coverage x4.5618.4 0.7%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.7 93.6%   
Return on assets %11.717.3 67.5%  
Return on equity %14.219.8 71.5%  
Return on capital %20.726.1 79.4%  
Exports to sales %39.40-   
Imports to sales %5.725.2 22.6%   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m42110,259 4.1%   
Fx inflow Rs m3,44535,384 9.7%   
Fx outflow Rs m70310,399 6.8%   
Net fx Rs m2,74324,985 11.0%   
CASH FLOW
From Operations Rs m1,44011,493 12.5%  
From Investments Rs m-1,089-11,372 9.6%  
From Financial Activity Rs m-353-93 378.8%  
Net Cashflow Rs m-128 -5.2%  

Share Holding

Indian Promoters % 52.0 52.0 100.1%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 11.8 66.4%  
FIIs % 16.6 19.0 87.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.2 151.2%  
Shareholders   25,395 31,796 79.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Over 220 Points Lower; Telecom Stocks Bleed(Closing)

After opening the day marginally lower, share markets in India witnessed selling pressure throughout the day and ended the day on a weak note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Dine with Ivanka; Waltz with Salman!(The Honest Truth)

Dec 1, 2017

A Saudi template to solve Indian government's tax deficit problem.

If You're Not Looking for 'Excitement' but 'Big Returns' from Stocks, This Is for You(The 5 Minute Wrapup)

Dec 7, 2017

One does not have to necessarily invest only in 'exciting' stocks to become wealthy.

Using Deposits to Rescue Banks is a Bad Idea; It Needs to Be Nipped in the Bud(Vivek Kaul's Diary)

Dec 11, 2017

The Financial Resolution and Deposit Insurance(FRDI) Bill proposes to do just this.

Beat Fund Managers at Their Own Game with These Stocks(Smart Contrarian)

Dec 6, 2017

The road to big investment gains passes through this universe.

IPOs Underperform Broad Market Indices(Chart Of The Day)

Nov 30, 2017

How did the IPOs perform in 2017 compared to broad market indices?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Dec 12, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS